https://www.selleckchem.com/products/jsh-150.html
Patient-reported outcomes (PROs) promote patient-centeredness in clinical trials; however, in the field of the rapidly emerging and clinically impressive immunotherapy, data on PROs are limited. We systematically identified all immunotherapy approvals from 2011 through 2018 and assessed the analytic tools and reporting quality of associated PRO reports. For randomized clinical trials (RCTs), we developed a novel 24-point scoring scale the PRO Endpoints Analysis Score (PROEAS) based on 24 criteria derived from the recommendations of the
Like
Comment
Share
